HIV reservoirs as obstacles and opportunities for an HIV cure

Nature Immunology

Volumn 16, Issue 6, 2015, Pages 584-589

  Chun, Tae Wook ^a   Moir, Susan ^a   Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; INTERLEUKIN 2; ANTIRETROVIRUS AGENT;

CYTOPATHOGENIC EFFECT; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; VACCINATION; VIRAL CLEARANCE; VIREMIA; DISEASE CARRIER; DRUG EFFECTS; HIV INFECTIONS; PHYSIOLOGY; TRANSMISSION; VIROLOGY; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS LOAD;

ANTI-RETROVIRAL AGENTS; DISEASE RESERVOIRS; HIV; HIV INFECTIONS; HUMANS; VIRAL LOAD; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84929853490     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.3152     Document Type: Review

References (63)

1. UN Joint Programme on HIV/AIDS (UNAIDS). Global Report: UNAIDS Report on the Global AIDS Epidemic 2013 http://www. unaids. org/sites/default/files/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS-Global-Report-2013-en. pdf (UNAIDS, 2013).
2. Johnson, L. F. et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med. 10, e1001418 (2013).
3. Nakagawa, F. , May, M. & Phillips, A. Life expectancy living with HIV: recent estimates and future implications. Curr. Opin. Infect. Dis. 26, 17-25 (2013).
4. Davey, R. T. Jr. et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. USA 96, 15109-15114 (1999).
5. Deeks, S. G. et al. Towards an HIV cure: a global scientific strategy. Nat. Rev. Immunol. 12, 607-614 (2012).
6. Chun, T. W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94, 13193-13197 (1997).
7. Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295-1300 (1997).
8. Wong, J. K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291-1295 (1997).
9. Siliciano, J. D. et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9, 727-728 (2003).
10. Chomont, N. et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15, 893-900 (2009).
11. Chun, T. W. et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J. Clin. Invest. 115, 3250-3255 (2005).
12. Fletcher, C. V. et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc. Natl. Acad. Sci. USA 111, 2307-2312 (2014).
13. Cory, T. J. , Schacker, T. W. , Stevenson, M. & Fletcher, C. V. Overcoming pharmacologic sanctuaries. Curr. Opin. HIV AIDS 8, 190-195 (2013).
14. Maldarelli, F. et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345, 179-183 (2014).
15. Wagner, T. A. et al. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 345, 570-573 (2014).
16. Cohn, L. B. et al. HIV-1 integration landscape during latent and active infection. Cell 160, 420-432 (2015).
17. Chun, T. W. et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183-188 (1997).
18. Ho, Y. C. et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155, 540-551 (2013).
19. Chun, T. W. et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat. Med. 5, 651-655 (1999).
20. Prins, J. M. et al. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 13, 2405-2410 (1999).
21. Perelson, A. S. et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387, 188-191 (1997).
22. Chun, T. W. , Davey, R. T. Jr. , Engel, D. , Lane, H. C. & Fauci, A. S. Re-emergence of HIV after stopping therapy. Nature 401, 874-875 (1999).
23. Lehrman, G. et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366, 549-555 (2005).
24. Margolis, D. M. Histone deacetylase inhibitors and HIV latency. Curr. Opin. HIV AIDS 6, 25-29 (2011).
25. Archin, N. M. et al. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS 22, 1131-1135 (2008).
26. Routy, J. P. et al. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med. 13, 291-296 (2012).
27. Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482-485 (2012).
28. Elliott, J. H. et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog. 10, e1004473 (2014).
29. Rasmussen, T. A. et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 1, e13-e21 (2014).
30. Blazkova, J. et al. Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4+ T cells from infected individuals receiving effective antiretroviral therapy. J. Infect. Dis. 206, 765-769 (2012).
31. Bullen, C. K. , Laird, G. M. , Durand, C. M. , Siliciano, J. D. & Siliciano, R. F. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat. Med. 20, 425-429 (2014).
32. Shan, L. et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36, 491-501 (2012).
33. Deng, K. et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517, 381-385 (2015).
34. Hütter, G. et al. Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. N. Engl. J. Med. 360, 692-698 (2009).
35. Yukl, S. A. et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog. 9, e1003347 (2013).
36. Kordelas, L. et al. Shift of HIV tropism in stem-cell transplantation with CCR5 delta32 mutation. N. Engl. J. Med. 371, 880-882 (2014).
37. Hütter, G. More on shift of HIV tropism in stem-cell transplantation with CCR5 delta32/delta32 mutation. N. Engl. J. Med. 371, 2437-2438 (2014).
38. Henrich, T. J. et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann. Intern. Med. 161, 319-327 (2014).
39. Tebas, P. et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370, 901-910 (2014).
40. Stone, D. , Kiem, H. P. & Jerome, K. R. Targeted gene disruption to cure HIV. Curr. Opin. HIV AIDS 8, 217-223 (2013).
41. Walker, B. D. & Yu, X. G. Unravelling the mechanisms of durable control of HIV-1. Nat. Rev. Immunol. 13, 487-498 (2013).
42. Chun, T. W. et al. Effect of antiretroviral therapy on HIV reservoirs in elite controllers. J. Infect. Dis. 208, 1443-1447 (2013).
43. Hatano, H. et al. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J. Virol. 83, 329-335 (2009).
44. Mens, H. et al. HIV-1 continues to replicate and evolve in patients with natural control of HIV infection J. Virol. 84, 12971-12981 (2010).
45. Migueles, S. A. & Connors, M. Long-term nonprogressive disease among untreated HIV-infected individuals: clinical implications of understanding immune control of HIV. J. Am. Med. Assoc. 304, 194-201 (2010).
46. Chun, T. W. et al. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 95, 8869-8873 (1998).
47. Whitney, J. B. et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512, 74-77 (2014).
48. Zhang, L. et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 340, 1605-1613 (1999).
49. Chun, T. W. et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J. Infect. Dis. 195, 1762-1764 (2007).
50. Hecht, F. M. et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J. Infect. Dis. 194, 725-733 (2006).
51. Persaud, D. et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N. Engl. J. Med. 369, 1828-1835 (2013).
52. Sáez-Cirión, A. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 9, e1003211 (2013).
53. Luzuriaga, K. et al. Viremic relapse after HIV-1 remission in a perinatally infected child. N. Engl. J. Med. 372, 786-788 (2015).
54. Corey, L. et al. HIV-1 vaccines and adaptive trial designs. Sci. Transl. Med. 3, 79ps13 (2011).
55. Burton, D. R. et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 12, 396-407 (2012).
56. Carcelain, G. & Autran, B. Immune interventions in HIV infection. Immunol. Rev. 254, 355-371 (2013).
57. Moir, S. , Malaspina, A. & Fauci, A. S. Prospects for an HIV vaccine: leading B cells down the right path. Nat. Struct. Mol. Biol. 18, 1317-1321 (2011).
58. Chun, T. W. et al. Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir. Proc. Natl. Acad. Sci. USA 111, 13151-13156 (2014).
59. Barouch, D. H. et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224-228 (2013).
60. Shingai, M. et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503, 277-280 (2013).
61. Halper-Stromberg, A. et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158, 989-999 (2014).
62. Barouch, D. H. & Deeks, S. G. Immunologic strategies for HIV-1 remission and eradication. Science 345, 169-174 (2014).
63. Eriksson, S. et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog. 9, e1003174 (2013).